Bbva Compass Bancshares Inc. Has $15.35 Million Stake in Abbott Laboratories (ABT)
Bbva Compass Bancshares Inc. lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 8.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 251,582 shares of the healthcare product maker’s stock after acquiring an additional 18,862 shares during the quarter. Abbott Laboratories makes up 1.0% of Bbva Compass Bancshares Inc.’s holdings, making the stock its 20th biggest holding. Bbva Compass Bancshares Inc.’s holdings in Abbott Laboratories were worth $15,345,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently modified their holdings of the company. SWS Partners bought a new position in shares of Abbott Laboratories during the fourth quarter worth about $104,000. Rainier Group Investment Advisory LLC bought a new position in shares of Abbott Laboratories during the first quarter worth about $114,000. FNY Investment Advisers LLC bought a new position in shares of Abbott Laboratories during the second quarter worth about $118,000. Private Ocean LLC raised its position in shares of Abbott Laboratories by 9,868.2% during the first quarter. Private Ocean LLC now owns 2,193 shares of the healthcare product maker’s stock worth $131,000 after acquiring an additional 2,171 shares during the last quarter. Finally, We Are One Seven LLC bought a new position in shares of Abbott Laboratories during the fourth quarter worth about $138,000. Institutional investors own 71.80% of the company’s stock.
Shares of ABT stock opened at $63.43 on Tuesday. The company has a market capitalization of $112.33 billion, a price-to-earnings ratio of 25.37, a price-to-earnings-growth ratio of 1.79 and a beta of 1.53. The company has a quick ratio of 1.16, a current ratio of 1.58 and a debt-to-equity ratio of 0.64. Abbott Laboratories has a fifty-two week low of $48.58 and a fifty-two week high of $65.90.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 15th. Shareholders of record on Friday, July 13th will be paid a $0.28 dividend. The ex-dividend date is Thursday, July 12th. This represents a $1.12 dividend on an annualized basis and a yield of 1.77%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 44.80%.
In other Abbott Laboratories news, insider Sharon J. Bracken sold 615 shares of the firm’s stock in a transaction that occurred on Monday, July 30th. The stock was sold at an average price of $65.16, for a total value of $40,073.40. Following the completion of the sale, the insider now owns 40,761 shares of the company’s stock, valued at $2,655,986.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Brian J. Blaser sold 15,100 shares of the firm’s stock in a transaction that occurred on Tuesday, July 24th. The shares were sold at an average price of $63.96, for a total value of $965,796.00. Following the completion of the sale, the executive vice president now directly owns 151,718 shares of the company’s stock, valued at approximately $9,703,883.28. The disclosure for this sale can be found here. Insiders sold 20,024 shares of company stock valued at $1,272,440 in the last three months. Insiders own 0.74% of the company’s stock.
A number of brokerages have recently issued reports on ABT. Royal Bank of Canada restated a “buy” rating and set a $70.00 price objective on shares of Abbott Laboratories in a research report on Thursday, July 19th. Stifel Nicolaus raised their price objective on Abbott Laboratories from $71.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, July 19th. Zacks Investment Research downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, August 6th. Sanford C. Bernstein began coverage on Abbott Laboratories in a research report on Wednesday, June 27th. They set an “outperform” rating and a $73.00 price objective for the company. Finally, Citigroup lowered their price objective on Abbott Laboratories from $66.00 to $65.00 and set a “neutral” rating for the company in a research report on Tuesday, April 24th. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $69.88.
About Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.
See Also: How to Invest in Marijuana Stocks
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.